Literature DB >> 34694452

Autofluorescence imaging within the liver: a promising tool for the detection and characterization of primary liver tumors.

Charlotte Benoit1, Aurélie Rodrigues1,2, Julien Calderaro3,4, Cécile Charpy4, Sylvie Simonin5, Jean-Charles Deybach5,6, Laurent Gouya5,6, Hervé Puy5,6, Caroline Schmitt5,6, René Farcy7, Valérie Vilgrain8, Valérie Paradis9, Nicolas Pote9, Fouad Lafdil2,3,10, Sébastien Mule2,3,11, Emmanuel Itti3,12, Alain Luciani13,14,15.   

Abstract

OBJECTIVES: To assess the performance of 405 nm-induced autofluorescence for the characterization of primary liver nodules on ex vivo resected specimens.
MATERIALS AND METHODS: Forty resected liver specimens bearing 53 primary liver nodules were included in this IRB-approved prospective study. Intratissular spectroscopic measurements were performed using a 25-G fibered-needle on all ex vivo specimens: 5 autofluorescence measurements were performed in both nodules and adjacent parenchyma. The spectra derivatives of the 635 and 670 nm autofluorescence peaks observed in nodules and in adjacent liver parenchyma were compared (Kruskal-Wallis and Mann-Whitney when appropriate).
RESULTS: A total of 42 potentially evolutive primary liver nodules-34 hepatocellular carcinomas, 4 intrahepatic cholangiocarcinomas, 4 hepatocellular adenomas-and 11 benign nodules-5 focal nodular hyperplasias, 6 regenerative nodules-were included. Both 635 and 670 nm Δderivatives were significantly higher in benign as compared to potentially evolutive (PEV) nodules (respectively 32.9 ± 4.5 vs 15.3 ± 1.4; p < 0.0001 and 5.7 ± 0.6 vs 2.5 ± 0.1; p < 0.0001) with respective sensitivity and specificity of 78% and 91% for distinguishing PEV from benign nodules.
CONCLUSION: 405 nm-induced autofluorescence enables the discrimination of benign from PEV primary liver nodules, suggesting that autofluorescence imaging could be used to optimize US targeted liver biopsies. KEY POINTS: • 405 nm-induced autofluorescence can distinguish liver tumors from the adjacent liver parenchyma. • The analysis of autofluorescence imaging observed within primary liver tumors can discriminate benign tumors from those requiring follow-up or targeted liver biopsy. • In current practice, autofluorescence imaging could be embedded within biopsy needle, to enable, in addition to ultrasound guidance, optimal targeting of liver nodules which could optimize tissue sampling.
© 2021. European Society of Radiology.

Entities:  

Keywords:  Biopsy; Diagnosis; Fluorescence; Liver neoplasms; Optical imaging

Mesh:

Year:  2021        PMID: 34694452     DOI: 10.1007/s00330-021-08307-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  36 in total

1.  Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver.

Authors:  A Rode; B Bancel; P Douek; M Chevallier; V Vilgrain; G Picaud; L Henry; F Berger; T Bizollon; J L Gaudin; C Ducerf
Journal:  J Comput Assist Tomogr       Date:  2001 May-Jun       Impact factor: 1.826

Review 2.  Diagnosis of hepatocellular carcinoma: An update on international guidelines.

Authors:  C Cassinotto; C Aubé; A Dohan
Journal:  Diagn Interv Imaging       Date:  2017-04-05       Impact factor: 4.026

3.  Differentiation of focal nodular hyperplasia from hepatocellular adenomas with low-mechanical-index contrast-enhanced sonography (CEUS): effect of size on diagnostic confidence.

Authors:  Vincent Roche; Frederic Pigneur; Lambros Tselikas; Marion Roux; Laurence Baranes; Marjane Djabbari; Charlotte Costentin; Julien Calderaro; Alexis Laurent; Alain Rahmouni; Alain Luciani
Journal:  Eur Radiol       Date:  2014-08-14       Impact factor: 5.315

4.  Management of 155 patients with benign liver tumours.

Authors:  C K Charny; W R Jarnagin; L H Schwartz; H S Frommeyer; R P DeMatteo; Y Fong; L H Blumgart
Journal:  Br J Surg       Date:  2001-06       Impact factor: 6.939

5.  Focal nodular hyperplasia of the liver: assessment with contrast-enhanced TurboFLASH MR imaging.

Authors:  D Mathieu; A Rahmouni; M C Anglade; B Falise; C Beges; P Gheung; J J Mollet; N Vasile
Journal:  Radiology       Date:  1991-07       Impact factor: 11.105

6.  Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.

Authors:  Ahmed Ba-Ssalamah; Wolfgang Schima; Maria T Schmook; Ken F Linnau; Nadja Schibany; Thomas Helbich; Peter Reimer; Friedrich Laengle; Friedrich Wrba; Amir Kurtaran; Mark Ryan; Frederick A Mann
Journal:  AJR Am J Roentgenol       Date:  2002-12       Impact factor: 3.959

Review 7.  Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis.

Authors:  Yoon Jin Lee; Jeong Min Lee; Ji Sung Lee; Hwa Young Lee; Bo Hyun Park; Young Hoon Kim; Joon Koo Han; Byung Ihn Choi
Journal:  Radiology       Date:  2015-01-05       Impact factor: 11.105

Review 8.  2014 KLCSG-NCC Korea Practice Guidelines for the management of hepatocellular carcinoma: HCC diagnostic algorithm.

Authors:  Jeong Min Lee; Joong-Won Park; Byung Ihn Choi
Journal:  Dig Dis       Date:  2014-10-29       Impact factor: 2.404

9.  Focal nodular hyperplasia and hepatic adenoma: comparison of angiography, CT, US, and scintigraphy.

Authors:  T J Welch; P F Sheedy; C M Johnson; D H Stephens; J W Charboneau; M L Brown; G R May; M A Adson; D B McGill
Journal:  Radiology       Date:  1985-09       Impact factor: 11.105

10.  MRI of atypical focal nodular hyperplasia of the liver: radiology-pathology correlation.

Authors:  Sophie Ferlicot; Hicham Kobeiter; Jeanne Tran Van Nhieu; Daniel Cherqui; Daniel Dhumeaux; Didier Mathieu; Elie Serge Zafrani
Journal:  AJR Am J Roentgenol       Date:  2004-05       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.